Vernakalant versus procainamide for rapid cardioversion of patients with acute atrial fibrillation (RAFF4): randomised clinical trial.

ABSTRACT:

Objective

To conduct a randomised, open label comparison of the effectiveness and safety of intravenous vernakalant and intravenous procainamide for the management of acute atrial fibrillation in the emergency department.

Design

Randomised clinical trial (RAFF4 trial).

Setting

12 tertiary care emergency departments in Canada.

Participants

Patients with acute atrial fibrillation for whom acute rhythm control was a safe option.

Interventions

Patients were randomised (1:1) to an intravenous infusion of vernakalant or procainamide; when rapid conversion did not occur, patients were offered electrical cardioversion.

Main outcomes and measures

The primary outcome was conversion to sinus rhythm within 30 minutes of drug infusion completion. Secondary out

SUBMITTER: Stiell IG 

PROVIDER: S-EPMC12603894 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature